Ouabain changes arterial blood pressure and vascular reactivity to phenylephrine in L-NAME-induced hypertension

Journal of Cardiovascular Pharmacology

Volumn 41, Issue 1, 2003, Pages 105-116

  Rossoni, Luciana V ^a   Dos Santos, Leonardo ^a   Barker, Louis A ^b   Vassallo, Dalton V ^a  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EDHF; Endothelium; L NAME; Nitric oxide; Ouabain; Phenylephrine; Vascular smooth muscle

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); HEXAMETHONIUM; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; OUABAIN; PHENYLEPHRINE; POTASSIUM CHANNEL STIMULATING AGENT; SODIUM; TETRYLAMMONIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; GANGLION BLOCK; HYPERTENSION; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; SODIUM CELL LEVEL; SYMPATHETIC TONE; TAIL ARTERY; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANIMALS; BLOOD PRESSURE; DRUG SYNERGISM; HYPERTENSION; MALE; MUSCLE, SMOOTH, VASCULAR; NG-NITROARGININE METHYL ESTER; OUABAIN; PHENYLEPHRINE; POTASSIUM CHANNELS; RATS; RATS, WISTAR;

EID: 0037215391     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200301000-00014     Document Type: Article

References (50)

1. Blaustein MP, Hamlyn JM. The pathogenesis of essential hypertension: A link between dietary salt and high blood pressure. Hypertension 1991;18(suppl III):III184-95.
2. Lüscher TF, Yang Z, Diederich D, et al. Endotheliumderived vasoactive substances: Potential role in hypertension, atherosclerosis, and vascular occlusion. J Cardiovasc Pharmacol 1989;14(suppl 6):S63-9.
3. Vanhoutte PM. Endothelium and control of vascular function: State of the art lecture. Hypertension 1989;13(3 pt 2): 658-67.
4. Krieger EM. Neurogenic hypertension in the rat. Circ Res 1964;15:511-21.
5. Abboud FM. The sympathetic system in hypertension: State of the art review. Hypertension 1982;4(3 pt 2):208-25.
6. Ludens JH, Clark MA, Robinson FG, et al. Rat adrenal cortex is a source of a circulating ouabain-like compound. Hypertension 1992;19:721-4.
7. Hamlyn JM, Blaustein MP, Bova S, et al. Identification and characterization of an ouabain-like compound from human plasma. Proc Natl Acad Sci U S A 1991;88:6259-63.
8. +) ATPase associated with essential hypertension. Nature 1982;300:650-2.
9. Yuan CM, Manunta P, Hamlyn JM, et al. Long-term ouabain administration produces hypertension in rats. Hypertension 1993;22:178-87.
10. Manunta P, Rogowski AC, Hamilton BP, et al. Ouabaininduced hypertension in the rat: Relationships among circulating and tissue ouabain and blood pressure. J Hypertens 1994;12:549-60.
11. Rossoni LV, Salaices M, Miguel M, et al. Ouabain-induced hypertension is accompanied by increases in endothelial vasodilator factors. Am J Physiol Heart Circ Physiol 2002;283:H2110-8.
12. Goto A, Yamada K, Yagi N, et al. Physiology and pharmacology of endogenous digitalis-like factors. Pharmacol Rev 1992;44:377-99.
13. 2+ stores and cell responsiveness. Am J Physiol 1993;264:C1367-87.
14. Blaustein MP, Juhaszova M, Golovina VA. The cellular mechanism of action of cardiotonic steroids: A new hypothesis. Clin Exper Hypertens 1998;20:691-703.
15. Vassallo DV, Songu-Mize E, Rossoni LV, et al. Effects of ouabain on vascular reactivity. Braz J Med Biol Res 1997; 30:545-52.
16. Songu-Mize E, Vassallo DV, Rashed SM, et al. Ouabain amplifies contractile responses to phenylephrine in rat tail arteries in hypertension. J Basic Clin Physiol Pharmacol 1995;6:309-19.
17. Zhu Z, Tepel M, Neusser M, et al. Low concentrations of ouabain increase cytosolic free calcium concentration in rat vascular smooth muscle cells. Clin Sci 1996;90:9-12.
18. Rossoni LV, Cunha V, França A, et al. The influence of nanomolar ouabain on vascular pressor responses is modulated by the endothelium. J Cardivasc Pharmacol 1999;34: 887-982.
19. Ponte A, Marín J, Arribas S, et al. Endothelial modulation of ouabain-induced contraction and sodium pump activity in aortas of normotensive Wistar-Kyoto and spontaneously hypertensive rats. J Vasc Res 1996;33:164-74.
20. Sánchez-Ferrer CF, Fernández-Alfonso MS, Ponte A, et al. Endothelial modulation of the ouabain-induced contraction in human placental vessels. Circ Res 1992;71:943-50.
21. Xie J, Wang Y, Summer WR, et al. Ouabain enhances basal release of nitric oxide from carotid artery. Am J Med Sci 1993;305:157-63.
22. Pacheco ME, Marfn J, Manso AM, et al. Nitric oxide synthase induction by ouabain in vascular smooth muscle cells from normotensive and hypertensive rats. J Hypertens 2000;18:877-84.
23. Ribeiro MO, Antunes E, de Nucci G, et al. Chronic inhibition of nitric oxide synthesis: A new model of arterial hypertension. Hypertension 1992;20:298-303.
24. Cunha RS, Cabral AM, Vasquez EC. Evidence that the autonomic nervous system plays a major role in the L-NAME-induced hypertension in conscious rats. Am J Hypertens 1993;6:806-9.
25. Maeso R, Navarro-Cid J, Rodrigo E, et al. Effects of antihypertensive therapy on factors mediating endothelium-dependent relaxation in rats treated chronically with L-NAME. J Hypertens 1999;17:221-7.
26. da Cunha V, Rossoni LV, Oliveira PA, et al. Cyclooxygenase inhibitor reduces blood pressure elevation and vascular reactivity dysfunction caused by inhibition of nitric oxide synthase in rat. Clin Exp Hypertens 2000;22:203-15.
27. Ruiz-Marcos FM, Ortíz MC, Fortepiani LA, et al. Mechanisms of the increased pressor response to vasopressors in the mesenteric bed of nitric oxide-deficient hypertensive rats. Eur J Pharmacol 2001;412:273-9.
28. Rossoni LV, Pinto VD, Vassallo DV. Effects of small doses of ouabain on the arterial blood pressure of anesthetized hypertensive and normotensive rats. Braz J Med Biol Res 2001;34:1065-77.
29. França AS, Rossoni LV, Amaral SMC, et al. Reactivity of the isolated perfused rat tail vascular bed. Braz J Med Biol Res 1997;30:891-5.
30. + ATPase activity in the vascular smooth muscle. Blood Vessels 1978;15:198-207.
31. Marín J, Redondo J. Vascular sodium pump: Endothelial modulation and alterations in some pathologic processes and aging. Pharmacol Ther 1999;84:249-71.
32. Songu-Mize E, Bealer SL, Calwell RW. Phasic vascular sodium pump changes in deoxycorticosterone-hypertensive rats. Circ Res 1984;55:304-8.
33. +-TPase inhibitor in the plasma of normotensive and hypertensive humans and rats. Hypertension 1987;10 (suppl 1):152-6.
34. Kojina I. Circulating digitalis-like substance is increased in DOCA-salt hypertension. Biochem Biophys Res Com 1984;122:129-36.
35. Davel APC, Rossoni LV, Vassallo DV. Effects of ouabain on the pressor response to phenylephrine and on the sodium pump activity in diabetic rats. Eur J Pharmacol 2000;406:419-27.
36. +-ATPase inhibitors and the adrenergic neuroeffector interaction in blood vessel wall. J Cardiovasc Pharmacol 1984;6(suppl 1):88-94.
37. Marín J, Sánchez-Ferrer CF, Salaices M. Effects of ouabain on isolated cerebral and femoral arteries of the cat: A functional and biochemical study. Br J Pharmacol 1988; 93:43-52.
38. Barker LA, Rossoni LV, Vassallo DV. Acute pressor actions of ouabain do not enhance the actions of phenylephrine or norepinephrine in anesthetized rats. J Cardiovasc Pharmacol 2001;37:339-48.
39. Guthrie GP Jr. Effects of digoxin on responsiveness to pressor actions of angiotensin and norepinephrine in man. J Clin Endoc Metab 1984;58:76-80.
40. Ceron PIB, Bendhack LM. Increased contractile response induced with ouabain is abolished by thapsigargin in aorta of renal hypertensive rats. Gen Pharmacol 1997;29:707-12.
41. Weiss DN, Podberesky DJ, Heidrich J, et al. Nanomolar ouabain augments caffeine-evoked contractions in rats arteries. Am J Physiol 1994;265:C1443-8.
42. França AS, Cunha V, Vassallo DV (Spon: Varner KJ). Role of endothelium in the ouabain-enhanced response to phenylephrine (Phe) (abstract). FASEB J 1997;11:A80.
43. Woolfson RG, Poston L. Effect of Ouabain on endothelium-dependent relaxation of human resistance arteries. Hypertension 1991;17:619-25.
44. Félétou M, Vanhoutte PM. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br J Pharmacol 1988;93:515-24.
45. Vrbjar N, Bernátová I, Pechánová O. Changes of sodium and ATP affinities of the cardiac (Na, K)-ATPase during and after nitric oxide deficient hypertension. Mol Cell Biochem 1999;202:141-7.
46. + pump activity by insulin and nitric oxide in rabbit aorta. Am J Physiol 1996;270:H1287-93.
47. Manunta P, Hamilton BP, Hamlyn, JM. Structure-activity relationships for the hypertensinogenic activity of ouabain: Role of the sugar and lactone ring. Hypertension 2001;37 (pt 2):472-7.
48. Abreu G, Futuro Neto HA, Cabral AM, et al. Ouabain produces diverse excitatory effects on afferent baroreceptor nerve activity in SHR and WKY animals. Clin Exper Hypertens 1998;20:85-94.
49. Abreu G, Futuro Neto HA, Cabral AM, et al. L-arginine restores the effect of ouabain on baroreceptor activity and prevents hypertension. Hypertension 1999;34(pt 2):729-32.
50. Budzikowski AS, Leenen FHH. Brain "ouabain" in the median preoptic nucleus mediates sodium-sensitive hypertension in spontaneously hypertensive rats. Hypertension 1997;29:599-605.